News Releases

<< Back
Prestige Brands Holdings, Inc. Reports Fiscal Third Quarter 2015 and Year-to-Date Results

Record Third Quarter Revenues Up 36.4%

Achieved Third Quarter Organic Growth of 2.1%

Outlook for Full Fiscal Year 2015 Updated

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Feb. 5, 2015-- Prestige Brands Holdings, Inc. (NYSE:PBH) today announced results for the third fiscal quarter and nine months ended December 31, 2014.

Key third quarter highlights include:

  • Revenue increased 36.4% to $197.6 million
  • Organic growth of 2.9% excluding the impact of foreign exchange
  • Adjusted FCF increased 9.6% to $45.5 million
  • Adjusted net income increased 63.0% to $25.4 million, or $0.48 per diluted share

“We are extremely pleased with our third quarter and year-to-date performance,” said Matthew M. Mannelly, President and CEO. “These results reflect continued strengthening of consumption trends among our core OTC brands as well as the addition of the recent acquisitions of Insight Pharmaceuticals (Insight) and Hydralyte. Sales increased across our core OTC and international categories resulting in record third quarter sales and organic growth of 2.9% after adjusting for the impact of foreign exchange, despite the challenging retail environment.”

Revenues in the third quarter increased 36.4% to a record $197.6 million, compared to $144.9 million in the third quarter of fiscal year 2014. Organic sales growth for the quarter was 2.1%, or 2.9% excluding the impact of foreign exchange, compared to the prior year comparable quarter. Reported net income totaled $21.3 million, or $0.40 per diluted share, compared to $3.1 million, or $0.06 per diluted share, in the third quarter of fiscal year 2014. Adjusted net income increased 63.0% to $25.4 million, or $0.48 per share, compared to $15.6 million, or $0.30 per share, in the third quarter of fiscal year 2014. Adjustments to net income in the third quarter of fiscal 2015 consist of items related to the acquisitions of Insight and Hydralyte. The prior year comparable quarter included adjustments related to a senior note offering.

Nine Months Ended December 31, 2014

Revenues for the nine months ended December 31, 2014 totaled a record $524.6 million, an increase of 15.5%, compared to $454.3 million for the nine months ended December 31, 2013. Reported net income totaled $54.5 million, or $1.04 per diluted share, compared to $56.6 million, or $1.08 per diluted share for the nine months ended December 31, 2013. Adjusted net income for the nine months ended December 31, 2014 totaled $73.3 million, or $1.39 per share, compared to adjusted net income of $61.3 million or $1.17 per share, for the nine months ended December 31, 2013. Adjustments to net income in the current year consist of items related to the Insight and Hydralyte acquisitions and primarily to the senior note offering and tax rate adjustments in the prior year.

Segment Review

North American OTC Healthcare. Revenues were $159.3 million for the third fiscal quarter of 2015, a 37.2% increase over third quarter 2014 revenues of $116.1 million. For the nine month period ended December 31, 2014, revenues totaled $407.3 million, compared to $367.5 million for the nine months ended December 31, 2013. Results for both periods were favorably impacted by increased consumption among core OTC brands as well as the Insight acquisition.

International OTC Healthcare. Revenues totaled $17.1 million for the third fiscal quarter of 2015, a 107.8% increase over third quarter 2014 revenues of $8.2 million. For the nine months ended December 31, 2014, revenues totaled $48.2 million, compared to $20.7 million for the nine months ended December 31, 2013. Results for both periods were impacted by revenues from the strong performance of the Care portfolio in Australia and the acquisition of Hydralyte.

Household Cleaning. Revenues totaled $21.2 million for the third fiscal quarter of 2015, a 3.4% increase over third quarter 2014 revenues of $20.5 million. Revenues for the nine months ended December 31, 2014 totaled $69.1 million, compared to $66.2 million for the nine months ended December 31, 2013.

Balance Sheet and Adjusted Free Cash Flow

Adjusted Free Cash Flow totaled $45.5 million for the third quarter of 2015, an increase of 9.6 % over fiscal third quarter 2014 Adjusted Free Cash Flow of $41.5 million. For the nine months ended December 31, 2014, Adjusted Free Cash Flow was $113.6 million compared to Adjusted Free Cash Flow of $95.0 million for the nine months ended December 31, 2013, an increase of 19.6 %. The Company repaid $55.0 million of debt during the third fiscal quarter of 2015 and had a bank-defined net debt to EBITDA leverage ratio of ~5.4.

Commentary & Outlook

“Our strong third quarter results underscore the strength of Prestige’s diverse and growing portfolio of brands, which are well-positioned to benefit over the long-term from our brand-building expertise and ability to bring innovative new products to the marketplace,” said Mr. Mannelly. “The recent additions of the Insight brands and Hydralyte continue to broaden our platform. Marketing and advertising initiatives are now in development for the newly acquired core OTC brands and we look forward to stabilizing, strengthening and building the new women’s health platform.”

Mr. Mannelly continued, “Third quarter results also reflect the strengthening of our financial profile. We are now increasing our Adjusted Free Cash Flow projection to approximately $155 million for fiscal year 2015, which will enable us to rapidly de-lever and continue to build meaningful M & A capacity.”

“In light of our excellent year to date and third quarter results, we are updating our previously provided outlook for fiscal year 2015,” said Mr. Mannelly. “We are tightening our expected adjusted EPS range from $1.75 to $1.85 per share to $1.82 to $1.85 per share, and anticipate revenue growth at the high end of our previously provided outlook of 15-18%. The update is driven by anticipated organic growth in the legacy business during the fourth quarter.”

Q3 Conference Call, Accompanying Slide Presentation & Replay

The Company will host a conference call to review its third quarter results on February 5, 2015 at 8:30 am EDT. The toll-free dial-in numbers are 877-280-4961 within North America and 857-244-7318 outside of North America. The conference pass code is "prestige". The Company will provide a live Internet webcast, a slide presentation to accompany the call, as well as an archived replay, all of which can be accessed from the Investor Relations page of the Company's website at http://prestigebrands.com. The slide presentation can be accessed just before the call from the Investor Relations page of the website by clicking on Webcasts and Presentations. Telephonic replays will be available for two weeks following the completion of the call and can be accessed at 888-286-8010 within North America and at 617-801-6888 from outside North America. The pass code is 28092338.

Non-GAAP Financial Information

In addition to financial results reported in accordance with generally accepted accounting principles (GAAP), we have provided certain non-GAAP financial information in this release to aid investors in understanding the Company's performance. Each non-GAAP financial measure is defined and reconciled to its most closely related GAAP financial measure in the “About Non-GAAP Financial Measures” section at the end of this earnings release.

About Prestige Brands Holdings, Inc.

The Company markets and distributes brand name over-the-counter and household cleaning products throughout the U.S. and Canada, and in certain international markets. Core brands include Monistat® women’s health products, Nix® lice treatment, Chloraseptic® sore throat treatments, Clear Eyes® eye care products, Compound W® wart treatments, The Doctor's® NightGuard® dental protector, the Little Remedies® and PediaCare® lines of pediatric over-the-counter products, Efferdent® denture care products, Luden's® throat drops, Dramamine® motion sickness treatment, BC® and Goody's® pain relievers, Beano® gas prevention, Debrox® earwax remover, and Gaviscon® antacid in Canada. Visit the Company's website at www.prestigebrands.com.

Note Regarding Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the federal securities laws that are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" generally can be identified by the use of forward-looking terminology such as "outlook," "may," "will," "would," "expect," “intend,” “estimate,” “anticipate,” “believe,” or "continue" (or the negative or other derivatives of each of these terms) or similar terminology. The "forward-looking statements" include, without limitation, statements regarding our positioning to benefit over the long term, our expected future operating results, including revenue growth, adjusted EPS, anticipated adjusted free cash flow, and our expected use of free cash flow for rapid deleveraging and building M&A capacity, new product introductions and our anticipated organic growth in the legacy business. These statements are based on management's estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those expected as a result of a variety of factors, including the impact of our advertising and promotional initiatives, competition in our industry, supplier issues, and the success of our brand-building investments and integration of newly acquired products. A discussion of other factors that could cause results to vary is included in the Company's Annual Report on Form 10-K for the year ended March 31, 2014, Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, and other periodic reports filed with the Securities and Exchange Commission.

 

 

Prestige Brands Holdings, Inc.

Consolidated Statements of Income and Comprehensive Income

(Unaudited)

 

Three Months Ended
December 31,

Nine Months Ended
December 31,

(In thousands, except per share data)

2014     2013   2014     2013  
Revenues
Net sales $ 196,435 $ 143,713 $ 520,981 $ 450,862
Other revenues 1,171   1,158   3,596   3,466  
Total revenues 197,606 144,871 524,577 454,328
 
Cost of Sales
Cost of sales (exclusive of depreciation shown below) 85,861   64,403   228,424   197,614  
Gross profit 111,745   80,468   296,153   256,714  
 
Operating Expenses
Advertising and promotion 30,144 24,229 74,284 67,457
General and administrative 19,454 12,137 63,588 35,390
Depreciation and amortization 5,154   3,644   11,967   10,206  
Total operating expenses 54,752   40,010   149,839   113,053  
Operating income 56,993   40,458   146,314   143,661  
 
Other (income) expense
Interest income (20 ) (16 ) (67 ) (44 )
Interest expense 24,612 21,276 57,505 53,648
Gain on sale of asset (1,133 ) (1,133 )
Loss on extinguishment of debt   15,012     15,012  
Total other expense 23,459   36,272   56,305   68,616  
Income before income taxes 33,534 4,186 90,009 75,045
Provision for income taxes 12,241   1,056   35,521   18,431  
Net income $ 21,293   $ 3,130   $ 54,488   $ 56,614  
 
Earnings per share:
Basic $ 0.41   $ 0.06   $ 1.05   $ 1.10  
Diluted $ 0.40   $ 0.06   $ 1.04   $ 1.08  
 
Weighted average shares outstanding:
Basic 52,278   51,806   52,110   51,498  
Diluted 52,730   52,445   52,622   52,236  
 
Comprehensive income, net of tax:
Currency translation adjustments (8,779 ) (2,694 ) (16,883 ) (1,571 )
Total other comprehensive loss (8,779 ) (2,694 ) (16,883 ) (1,571 )
Comprehensive income $ 12,514   $ 436   $ 37,605   $ 55,043  

 

Prestige Brands Holdings, Inc.

Consolidated Balance Sheets

(Unaudited)

 

(In thousands)

Assets

December 31,
2014
March 31,
2014
Current assets
Cash and cash equivalents $ 21,951 $ 28,331
Accounts receivable, net 87,692 65,050
Inventories 75,240 65,586
Deferred income tax assets 8,346 6,544
Prepaid expenses and other current assets 7,533   11,674  
Total current assets 200,762 177,185
 
Property and equipment, net 13,089 9,597
Goodwill 291,892 190,911
Intangible assets, net 2,144,084 1,394,817
Other long-term assets 30,769   23,153  
Total Assets $ 2,680,596   $ 1,795,663  
 
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable $ 38,567 $ 48,286
Accrued interest payable 11,792 9,626
Other accrued liabilities 40,675   26,446  
Total current liabilities 91,034   84,358  
 
Long-term debt
Principal amount 1,643,600 937,500
Less unamortized discount (5,639 ) (3,086 )
Long-term debt, net of unamortized discount 1,637,961   934,414  
 
Deferred income tax liabilities 342,385 213,204
Other long-term liabilities 279   327  
Total Liabilities 2,071,659   1,232,303  
 
 
Stockholders' Equity
Preferred stock - $0.01 par value
Authorized - 5,000 shares
Issued and outstanding - None
Common stock - $0.01 par value
Authorized - 250,000 shares
Issued - 52,508 shares at December 31, 2014 and 52,021 shares at March 31, 2014 525 520
Additional paid-in capital 423,985 414,387
Treasury stock, at cost - 255 shares at December 31, 2014 and 206 shares at March 31, 2014 (3,062 ) (1,431 )
Accumulated other comprehensive (loss) income, net of tax (16,144 ) 739
Retained earnings 203,633   149,145  
Total Stockholders' Equity 608,937   563,360  
Total Liabilities and Stockholders' Equity $ 2,680,596   $ 1,795,663  
 

Prestige Brands Holdings, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

 
Nine Months Ended December 31,

(In thousands)

2014     2013  
Operating Activities
Net income $ 54,488 $ 56,614
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 11,967 10,209
Gain on sale of asset (1,133 )
Deferred income taxes 19,517 10,261
Amortization of deferred financing costs 4,568 6,023
Stock-based compensation costs 4,919 3,763
Loss on extinguishment of debt 15,012
Premium payment on 2010 Senior Notes (12,768 )
Amortization of debt discount 1,336 3,115
Lease termination costs 1,125
Loss (gain) on sale or disposal of equipment 321 (3 )
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable 2,113 8,495
Inventories 14,478 (2,262 )
Prepaid expenses and other current assets 7,598 (2,783 )
Accounts payable (25,452 ) (1,285 )
Accrued liabilities 8,297   (13,531 )
Net cash provided by operating activities 104,142   80,860  
 

Investing Activities

Purchases of property and equipment (3,700 ) (2,658 )
Proceeds from the sale of property and equipment 3
Proceeds from sale of business 18,500
Proceeds from sale of asset 10,000
Acquisition of Insight Pharmaceuticals, less cash acquired (749,666 )
Acquisition of the Hydralyte brand (77,991 )
Acquisition of Care Pharmaceuticals, less cash acquired   (55,215 )
Net cash used in investing activities (802,857 ) (57,870 )
 
Financing Activities
Proceeds from issuance of 2013 Senior Notes 400,000
Repayment of 2010 Senior Notes (201,710 )
Term loan borrowings 720,000
Term loan repayments (80,000 ) (147,500 )
Borrowings under revolving credit agreement 124,600 50,000
Repayments under revolving credit agreement (58,500 ) (45,500 )
Payment of deferred financing costs (16,072 ) (6,933 )
Proceeds from exercise of stock options 3,654 5,738
Proceeds from restricted stock exercises 57
Excess tax benefits from share-based awards 1,030 1,725
Fair value of shares surrendered as payment of tax withholding (1,688 ) (278 )
Net cash provided by financing activities 693,081   55,542  
 
Effects of exchange rate changes on cash and cash equivalents (746 ) 151
(Decrease) increase in cash and cash equivalents (6,380 ) 78,683
Cash and cash equivalents - beginning of period 28,331   15,670  
Cash and cash equivalents - end of period $ 21,951   $ 94,353  
 
Interest paid $ 49,435   $ 47,586  
Income taxes paid $ 7,135   $ 9,761  
 

Prestige Brands Holdings, Inc.

Consolidated Statements of Income

Business Segments

(Unaudited)

 
Three Months Ended December 31, 2014  

(In thousands)

North

American

OTC

Healthcare

 

International

OTC

Healthcare

  Household

Cleaning

  Consolidated  
Gross segment revenues $ 160,655 $ 17,071 $ 20,218 $ 197,944
Elimination of intersegment revenues (1,509 )    

(1,509

)

 

Third-party segment revenues 159,146 17,071 20,218 196,435
Other revenues 151   4   1,016   1,171    
Total segment revenues 159,297 17,075 21,234 197,606
Cost of sales 63,479   6,247   16,135   85,861    
Gross profit 95,818 10,828 5,099 111,745
Advertising and promotion 26,779   2,776   589   30,144    
Contribution margin $ 69,039   $ 8,052   $ 4,510   81,601
Other operating expenses 24,608    
Operating income 56,993
Other expense 23,459    
Income before income taxes 33,534
Provision for income taxes 12,241    
Net income $ 21,293    
 
 
Nine Months Ended December 31, 2014

(In thousands)

North
American
OTC
Healthcare
  International
OTC
Healthcare
  Household
Cleaning
  Consolidated
Gross segment revenues $ 409,767 $ 48,093 $ 66,057 $ 523,917
Elimination of intersegment revenues (2,936 )     (2,936 )
Third-party segment revenues 406,831 48,093 66,057 520,981
Other revenues 478   62   3,056   3,596  
Total segment revenues 407,309 48,155 69,113 524,577
Cost of sales 158,005   17,926   52,493   228,424  
Gross profit 249,304 30,229 16,620 296,153
Advertising and promotion 64,573   8,151   1,560   74,284  
Contribution margin $ 184,731   $ 22,078   $ 15,060   221,869
Other operating expenses 75,555  
Operating income 146,314
Other expense 56,305  
Income before income taxes 90,009
Provision for income taxes 35,521  
Net income $ 54,488  
 
 
Three Months Ended December 31, 2013

(In thousands)

North
American

OTC

Healthcare

 

International

OTC

Healthcare

 

 

Household

Cleaning

  Consolidated
Gross segment revenues $ 117,476 $ 8,214 $ 19,532 $ 145,222
Elimination of intersegment revenues (1,509 )     (1,509 )
Third-party segment revenues 115,967 8,214 19,532 143,713
Other revenues 150     1,008   1,158  
Total segment revenues 116,117 8,214 20,540 144,871
Cost of sales 45,886   3,144   15,373   64,403  
Gross profit 70,231 5,070 5,167 80,468
Advertising and promotion 21,380   2,145   704   24,229  
Contribution margin $ 48,851   $ 2,925   $ 4,463   56,239
Other operating expenses 15,781  
Operating income 40,458
Other expense 36,272  
Income before income taxes 4,186
Provision for income taxes 1,056  
Net income $ 3,130  
Nine Months Ended December 31, 2013

(In thousands)

North

American

OTC

Healthcare

 

International

OTC

Healthcare

 

Household

Cleaning

  Consolidated
Gross segment revenues $ 369,356 $ 20,636 $ 63,198 $ 453,190
Elimination of intersegment revenues (2,328 )     (2,328 )
Third-party segment revenues 367,028 20,636 63,198 450,862
Other revenues 450   14   3,002   3,466  
Total segment revenues 367,478 20,650 66,200 454,328
Cost of sales 140,419   8,947   48,248   197,614  
Gross profit 227,059 11,703 17,952 256,714
Advertising and promotion 61,477   3,855   2,125   67,457  
Contribution margin $ 165,582   $ 7,848   $ 15,827   189,257
Other operating expenses 45,596  
Operating income 143,661
Other expense 68,616  
Income before income taxes 75,045
Provision for income taxes 18,431  
Net income $ 56,614  

About Non-GAAP Financial Measures

We define Non-GAAP Total Revenues excluding acquisitions and divestitures and the impact of current year foreign exchange rates as Total Revenues excluding revenues associated with products acquired or divested in the periods presented and the impact of current year foreign exchange rates on total revenues. We define Non-GAAP Adjusted EBITDA as earnings before interest expense (income), income taxes, depreciation and amortization, certain other legal and professional fees, and other acquisition-related costs. Non-GAAP Adjusted EBITDA margin is calculated as Non-GAAP Adjusted EBITDA divided by GAAP Total Revenues. We define Non-GAAP Adjusted Gross Margin as Gross Profit before inventory step up charges and certain other acquisition and integration-related costs. Non-GAAP Adjusted Gross Margin Percentage is calculated based on Non-GAAP Adjusted Gross Margin divided by GAAP Total Revenues. We define Non-GAAP Adjusted General and Administrative expenses as General and Administrative expenses minus certain other legal and professional fees, acquisition and other integration costs. Non-GAAP Adjusted General and Administrative expense percentage is calculated based on Non-GAAP Adjusted General and Administrative expense divided by GAAP Total Revenues. We define Non-GAAP Adjusted Net Income as Net Income before inventory step-up charges, certain other legal and professional fees, other acquisition and integration-related costs, the applicable tax impacts associated with these items and the tax impacts of state tax rate adjustments and other non-deductible items. Non-GAAP Adjusted EPS is calculated based on Non-GAAP Adjusted Net Income, divided by the weighted average number of common and potential common shares outstanding during the period. We define Non-GAAP Adjusted Free Cash Flow as net cash provided by operating activities less premium payments to extinguish debt, accelerated interest payments due to debt refinancing and cash paid for capital expenditures, plus payments for integration, transition and other payments associated with acquisitions. Non-GAAP Total Revenues excluding acquisitions and divestitures and the impact of current year foreign exchange rates, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Gross Margin Percentage, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense percentage, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, and Non-GAAP Adjusted Free Cash Flow may not be comparable to similarly titled measures reported by other companies.

We are presenting Non-GAAP Total Revenues excluding acquisitions and divestitures and exchange rates, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Gross Margin Percentage, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense percentage,Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, and Non-GAAP Adjusted Free Cash Flow, because they provide additional ways to view our operation when considered with both our GAAP results and the reconciliation to net income and net cash provided by operating activities, respectively, which we believe provides a more complete understanding of our business than could be obtained absent this disclosure. Each of Non-GAAP Total Revenues excluding acquisitions and divestitures and exchange rates, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Gross Margin Percentage, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense percentage, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, and Non-GAAP Adjusted Free Cash Flow, is presented solely as a supplemental disclosure because (i) we believe it is a useful tool for investors to assess the operating performance of the business without the effect of these items; (ii) we believe that investors will find this data useful in assessing shareholder value; and (iii) we use Non-GAAP Total Revenues excluding acquisitions and divestitures and exchange rates, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Gross Margin Percentage, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense percentage, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, and Non-GAAP Adjusted Free Cash Flow internally to evaluate the performance of our personnel and also as a benchmark to evaluate our operating performance or compare our performance to that of our competitors. The use of Non-GAAP Total Revenues excluding acquisitions and divestitures and exchange rates, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Gross Margin Percentage, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense percentage, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, and Non-GAAP Adjusted Free Cash Flow, have limitations, and you should not consider these measures in isolation from or as an alternative to GAAP measures such as General and Administrative expense, Operating income, Net income, and Net cash flow provided by operating activities, or cash flow statement data prepared in accordance with GAAP, or as a measure of profitability or liquidity.

The following tables set forth the reconciliation of Non-GAAP Total Revenues excluding acquisitions and divestitures and exchange rates, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Gross Margin Percentage, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense percentage, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, Non-GAAP Adjusted Free Cash Flow, all of which are non-GAAP financial measures, to GAAP Gross Profit, GAAP General and Administrative expense, GAAP Net Income, GAAP Diluted EPS and GAAP Net cash provided by operating activities, our most directly comparable financial measures presented in accordance with GAAP.

Reconciliation of GAAP Total Revenues to Non-GAAP Total Revenues excluding acquisitions and divestitures and exchange rates:

 

Three Months Ended
December 31,

 

Nine Months Ended

December 31,

2014     2013   2014     2013  
(In thousands)
GAAP Total Revenues $ 197,606   $ 144,871   $ 524,577   $ 454,328  
Adjustments:
Care Pharma and Hydralyte revenues (1) (6,250 ) (18,591 )
Insight revenues (2) (43,431 )   (56,090 )  
Total adjustments (49,681 )   (74,681 )  
Non-GAAP Total Revenues excluding acquisitions and divestitures 147,925   144,871   449,896   454,328  
Organic Revenue Growth (decline) 2.1 % (1.0 )%
Impact of current year foreign exchange rates (3) (1,065 ) (2,034 )
Non-GAAP Total Revenues excluding acquisitions and divestitures and impact of current year foreign exchange rates $ 147,925   $ 143,806   $ 449,896   $ 452,294  
Constant Currency Organic Revenue Growth (decline) 2.9 % (0.5 )%

(1) Revenue adjustments relate to our International OTC Healthcare segment

(2) Revenue adjustments relate to our North American OTC Healthcare segment

(3) Foreign exchange rate adjustments relate to all segments

 

Reconciliation of GAAP Gross Profit to Non-GAAP Adjusted Gross Margin and related Adjusted Gross Margin percentage:

 

Three Months Ended
December 31,

Nine Months Ended
December 31,

2014     2013   2014     2013  
(In thousands)
GAAP Total Revenues $ 197,606   $ 144,871   $ 524,577   $ 454,328  
 
GAAP Gross Profit $ 111,745   $ 80,468   $ 296,153   $ 256,714  

Adjustments:

Inventory step-up charges and other costs associated with

Care and Hydralyte acquisitions (1)

 

246 577

Inventory step-up charges associated with Insight

acquisition (2)

1,326 1,979
Care acquisition related inventory costs (1)       407  
Total adjustments 1,326     2,225   984  
Non-GAAP Adjusted Gross Margin $ 113,071   $ 80,468   $ 298,378   $ 257,698  
Non-GAAP Adjusted Gross Margin % 57.2 % 55.5 % 56.9 % 56.7 %

(1) Inventory step-up charges and other costs relate to our International OTC Healthcare segment

(2) Inventory step-up charges relate to our North American OTC Healthcare segment

 

Reconciliation of GAAP General and Administrative Expense to Non-GAAP Adjusted General and Administrative Expense and Non-GAAP Adjusted General and Administrative Expense percentage:

 

Three Months Ended
December 31,

Nine Months Ended
December 31,

2014     2013   2014     2013  
(In thousands)
GAAP General and Administrative Expense $ 19,454   $ 12,137   $ 63,588   $ 35,390  

Adjustments:

Legal and professional fees associated with acquisitions and divestitures 477 10,334 668
Stamp/Duty Tax on Australian acquisition 2,940
Integration, transition and other costs associated with acquisitions 5,181     9,613    
Total adjustments 5,658     22,887   668  
Non-GAAP Adjusted General and Administrative Expense $ 13,796   $ 12,137   $ 40,701   $ 34,722  
Non-GAAP Adjusted General and Administrative Expense Percentage 7.0 % 8.4 % 7.8 % 7.6 %
 

Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA and Non-GAAP Adjusted EBITDA margin:

 

Three Months Ended
December 31,

Nine Months Ended
December 31,

2014     2013   2014     2013  
(In thousands)
GAAP Net Income $ 21,293 $ 3,130 $ 54,488 $ 56,614
Interest expense, net 24,592 21,260 57,438 53,604
Provision for income taxes 12,241 1,056 35,521 18,431
Depreciation and amortization 5,154   3,644   11,967   10,206  
Non-GAAP EBITDA: 63,280   29,090   159,414   138,855  

Adjustments:

Inventory step-up charges and other costs associated with Care and Hydralyte acquisitions (1) 246 577
Inventory step-up charges associated with Insight acquisition (2) 1,326 1,979
Care acquisition related inventory costs (1) 407
Legal and professional fees associated with acquisitions and divestitures (3) 477 10,334 668
Stamp/Duty Tax on Australian acquisition (3) 2,940
Integration, transition and other costs associated with acquisitions (3) 5,181 9,613
Gain on sale of asset (1,133 ) (1,133 )
Loss on extinguishment of debt   15,012     15,012  
Total adjustments 5,851   15,012   23,979   16,664  
Non-GAAP Adjusted EBITDA $ 69,131   $ 44,102   $ 183,393   $ 155,519  
Non-GAAP Adjusted EBITDA Margin 35.0 % 30.4 % 35.0 % 34.2 %

(1) Inventory step-up charges and other costs relate to our International OTC Healthcare segment

(2) Inventory step-up charges relate to our North American OTC Healthcare segment

(3) Adjustments relate to G&A expenses
 

Reconciliation of GAAP Net Income to Non-GAAP Adjusted Net Income and related Adjusted Earnings Per Share:

Three Months Ended December 31,   Nine Months Ended December 31,
2014  

2014

Adjusted

EPS

  2013  

2013

Adjusted

EPS

2014  

2014

Adjusted

EPS

  2013  

2013

Adjusted

EPS

(In thousands)
GAAP Net Income $ 21,293   $ 0.40   $ 3,130   $ 0.06   $ 54,488   $ 1.04   $ 56,614   $ 1.08  

Adjustments:

Inventory step-up charges and other costs associated with Care and Hydralyte acquisitions (1) 246 577 0.01
Inventory step-up charges associated with Insight acquisition (2) 1,326 0.03 1,979 0.04
Care acquisition related inventory costs (1) 407 0.01
Legal and professional fees associated with acquisitions and divestitures (3) 477 0.01 10,334 0.20 668 0.01
Stamp/Duty Tax on Australian acquisition (3) 2,940 0.05
Integration, transition and other costs associated with acquisitions (3) 5,181 0.10 9,613 0.18
Accelerated amortization of debt discount and debt issue costs 218 5,112 0.10 218 5,112 0.10
Gain on sale of asset (1,133 ) (0.02 ) (1,133 ) (0.02 )
Loss on extinguishment of debt 15,012 0.29 15,012 0.29
Tax impact of adjustments (1,950 ) (0.04 ) (7,285 ) (0.14 ) (5,419 ) (0.10 ) (7,641 ) (0.15 )
Impact of state tax adjustments     (380 ) (0.01 )     (9,465 ) (0.18 )
Total adjustments 4,119   0.08   12,459   0.24   18,778   0.35   4,670   0.09  
Non-GAAP Adjusted Net Income and Adjusted EPS $ 25,412   $ 0.48   $ 15,589   $ 0.30   $ 73,266   $ 1.39   $ 61,284   $ 1.17  

(1) Inventory step-up charges and other costs relate to our International OTC Healthcare segment

(2) Inventory step-up charges relate to our North American OTC Healthcare segment

(3) Adjustments relate to G&A expenses

 

Reconciliation of GAAP Net Income to Adjusted Non-GAAP Free Cash Flow:

Three Months Ended
September 30,

 

Nine Months Ended

December 31,

2014     2013   2014     2013  
(In thousands)
GAAP Net Income $ 21,293   $ 3,130   $ 54,488   $ 56,614  

Adjustments:

Adjustments to reconcile net income to net cash provided by operating activities as shown in the Statement of Cash Flows 17,765 19,438 42,620 35,612
Changes in operating assets and liabilities, net of effects from acquisitions as shown in the Statement of Cash Flows 8,026   2,694   7,034   (11,366 )
Total adjustments 25,791   22,132   49,654   24,246  
GAAP Net cash provided by operating activities 47,084 25,262 104,142 80,860
 
Premium payment on 2010 Senior Notes 12,768 12,768
Accelerated interest payments due to debt refinancing 3,513 3,513
Purchases of property and equipment (2,320 ) (339 ) (3,700 ) (2,658 )
Non-GAAP Free Cash Flow 44,764 41,204 100,442 94,483
Integration, transition and other payments associated with acquisitions 784   337   13,201   512  
Adjusted Non-GAAP Free Cash Flow $ 45,548   $ 41,541   $ 113,643   $ 94,995  
 

Outlook for Fiscal Year 2015:

Reconciliation of Projected GAAP EPS to Projected Non-GAAP Adjusted EPS:

2015 Projected EPS
Low   High
Projected FY'15 GAAP EPS $ 1.35     $ 1.38

Adjustments:

 
Integration, transition and other costs associated with acquisitions 0.47     0.47
Total Adjustments 0.47     0.47
Projected Non-GAAP Adjusted EPS $ 1.82     $ 1.85
 

Reconciliation of Projected GAAP Net cash provided by operating activities to Projected Non-GAAP Adjusted Free Cash Flow:

2015

Projected Free

Cash Flow

 

(In millions)
Projected FY'15 GAAP Net cash provided by operating activities $ 146
Projected integration, transition and other costs associated with acquisitions 15
Additions to property and equipment for cash (6 )
Projected Non-GAAP Adjusted Free Cash Flow $ 155  

Source: Prestige Brands Holdings, Inc.

Prestige Brands Holdings, Inc.
Dean Siegal, 914-524-6819

Primary IR Contact

Irinquiries@prestigebrands.com
Prestige Consumer Healthcare Inc.
660 White Plains Road – Ste 250
Tarrytown, NY 10591
Telephone: 914-524-6819

Transfer Agent

AST
6201 15th Avenue
Brooklyn, NY 11219
Telephone: (800) 937-5449
help@astfinancial.com
https://www.astfinancial.com

Subscribe

Stay up to date with investor news, stock information and SEC filings.
Subscribe »